News | September 1, 2020

TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call Scheduling Acquisition bolsters collaboration across complex healthcare teams to drive efficiency in the COVID-19 era SANTA MONICA, Calif. — Sept. 1, 2020 —...

News | August 17, 2020

Sanofi to acquire Principia Biopharma Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future...

News | June 29, 2020

Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to...

News | May 15, 2020

FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor -QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3...

News | November 18, 2019

Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection London, UK, November 18, 2019 – ReViral Ltd., a clinical-stage company focused on developing novel, antiviral...

News | April 30, 2019

Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure...